PriceTargets.com logo

Pro-Dex - PDEX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $74.00
  • Forecasted Upside: 4.02%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$71.14 As of 09/16/2026 12:52 PM ET
▲ +4.233 (6.33%)

This chart shows the closing price for PDEX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pro-Dex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDEX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDEX

Analyst Price Target is $74.00
▲ +4.02% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pro-Dex in the last 3 months. The average price target is $74.00, with a high forecast of $74.00 and a low forecast of $74.00. The average price target represents a 4.02% upside from the last price of $71.14.

This chart shows the closing price for PDEX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 polled investment analysts is to moderate buy stock in Pro-Dex. This rating has held steady since July 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/11/2026Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$70.00 ➝ $74.00
9/4/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
8/24/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
8/6/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
7/17/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
7/1/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
5/19/2026Zacks ResearchUpgradeHold
5/12/2026Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$56.00 ➝ $70.00
5/1/2026Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/23/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/17/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/11/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/8/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
9/27/2025Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
5/27/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$54.00 ➝ $56.00
11/11/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$30.00 ➝ $52.00
9/9/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$28.00 ➝ $30.00
5/16/2022Ascendiant Capital MarketsLower TargetNA$30.00
(Data available from 9/16/2021 forward)

News Sentiment Rating

1.09 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Pro-Dex logo
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $71.14
Low: $67.05
High: $71.58

50 Day Range

MA: $62.68
Low: $53.43
High: $73.41

52 Week Range

Now: $71.14
Low: $23.47
High: $77.00

Volume

41,275 shs

Average Volume

50,982 shs

Market Capitalization

$227.87 million

P/E Ratio

17.26

Dividend Yield

N/A

Beta

0.06

Frequently Asked Questions

What sell-side analysts currently cover shares of Pro-Dex?

The following Wall Street analysts have issued research reports on Pro-Dex in the last twelve months: Ascendiant Capital Markets, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for PDEX.

What is the current price target for Pro-Dex?

0 Wall Street analysts have set twelve-month price targets for Pro-Dex in the last year. Their average twelve-month price target is $74.00, suggesting a possible upside of 4.0%. Ascendiant Capital Markets has the highest price target set, predicting PDEX will reach $74.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $74.00 for Pro-Dex in the next year.
View the latest price targets for PDEX.

What is the current consensus analyst rating for Pro-Dex?

Pro-Dex currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PDEX.

What other companies compete with Pro-Dex?

Other companies that are similar to Pro-Dex include Anteris Technologies Global, SiBone, Varex Imaging, Beta Bionics and SS Innovations International. Learn More about companies similar to Pro-Dex.

How do I contact Pro-Dex's investor relations team?

Pro-Dex's physical mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier's listed phone number is (949) 769-3200 and its investor relations email address is [email protected]. The official website for Pro-Dex is www.pro-dex.com. Learn More about contacing Pro-Dex investor relations.